software;
•
depreciation of computer equipment; and
•
depreciation of leasehold improvements, furniture and fixtures, and office equipment.
Depreciation and amortization expenses increased year-over-year in 2024 due primarily to increased depreciation of computer equipment, as well as amortization expense related to internally-developed and purchased software.
36
Transformation Costs
* Not meaningful
See "–Trends" above for additional information on the Transformation Program that we announced in November 2024. For the year ended December 31, 2024, the program related costs, which primarily consist of professional fees, are recorded in "Transformation costs" in the Consolidated Statement of Operations. See Note 20 to our Consolidated Financial Statements.
Other Operating Expenses
* Not meaningful
Interest Expense and Interest and Dividend Income
The following table presents the changes in interest expense and interest and dividend income for the years ended December 31, 2024 and 2023:
Interest expense increased for the year ended December 31, 2024, compared to the year ended December 31, 2023, primarily due to the amortization of debt discount related to convertible senior notes due May 2025 (see Note 12 to our Consolidated Financial Statements) and the senior notes issued in 2023 and 2024. Interest and dividend income increased for the year ended December 31, 2024, compared to the year ended December 31, 2023, primarily due to higher money market fund investment balances.
Other Income (Expense), Net
The following table sets forth the composition of "Other income (expense), net" for the years ended December 31, 2024 and 2023:
Foreign currency transaction gains (losses) for the year ended December 31, 2024 includes gains of $526 million related to our Euro-denominated debt and accrued interest that were not designated as net investment hedges and losses of $156 million on derivative contracts. Foreign currency transaction gains (losses) for the year ended December 31, 2023 includes losses of $163 million related to our Euro-denominated debt and accrued interest that were not designated as net investment hedges and losses of $106 million on derivative contracts.
See Notes 5 and 6 to our Consolidated Financial Statements for additional information related to net gains (losses) on equity securities.
See Note 12 to our Consolidated Financial Statements for additional information on the loss related to the conversion option on convertible senior notes.
37
Income Taxes
Our 2024 effective tax rate differs from the U.S. federal statutory tax rate of 21%, primarily due to the benefit of the Netherlands Innovation Box Tax (as defined below) and a reduction to the Company's 2018 federal one-time deemed repatriation liability, pursuant to the U.S. Tax Cuts and Jobs Act ("Tax Act"), resulting from a recent U.S. Tax Court decision in Varian Medical Systems, Inc. vs. Commissioner, partially offset by higher international tax rates, non-deductible expenses